12 Month Price Forecast For MDNAF
Distance to MDNAF Price Forecasts
MDNAF Price Momentum
๐ค Considering Medicenna (MDNAF)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 10, 2025 8:09 PM UTC
MDNAF Analyst Ratings & Price Targets
Based on our analysis of 1 Wall Street analysts, MDNAF has a consensus that is bullish. The median price target is $4.25, with forecasts ranging from $2.50 to $6.00. Currently, there are 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With MDNAF currently trading at $0.88, the median price forecast suggests a 382.4% upside. The most optimistic forecast comes from at , projecting a 581.0% upside, while at provides the most conservative target, suggesting a 183.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDNAF Analyst Consensus
MDNAF Price Target Range
Latest MDNAF Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDNAF.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
Dec 18, 2020 | Oppenheimer | Outperform | Initiates | $0.00 | |
Dec 17, 2020 | Oppenheimer | Outperform | Initiates | $0.00 | |
Sep 10, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 |
Stocks Similar to Medicenna Therapeutics Corp.
The following stocks are similar to Medicenna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medicenna Therapeutics Corp. (MDNAF) Financial Data
Medicenna Therapeutics Corp. has a market capitalization of $69.37M with a P/E ratio of -2.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -490.6%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Medicenna Therapeutics Corp. (MDNAF) Company Overview
About Medicenna Therapeutics Corp.
Develops immunotherapies for cancer treatment.
Medicenna Therapeutics Corp. focuses on developing and commercializing advanced immunotherapy treatments, specifically Superkines and empowered Superkines. The company generates revenue through the development of its proprietary therapies, which are designed to enhance the immune response against cancer and other diseases, and by offering its BiSKITs platform for the creation of customized Superkines.
Headquartered in Toronto, Canada, Medicenna is advancing multiple therapeutic candidates, including treatments for glioblastoma and various solid tumors. Their innovative approach could provide significant advancements in cancer therapy and potentially address unmet medical needs in both oncology and autoimmune diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Dr. Fahar Merchant Ph.D.
Country
Canada
IPO Year
2017
Website
www.medicenna.comMedicenna Therapeutics Corp. (MDNAF) Latest News & Analysis
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
5 days agoMedicenna Therapeutics Corp. will participate in two investor conferences in February 2025 and will conduct one-on-one meetings with investors. The company focuses on immunotherapy for cancer and autoimmune diseases.
Medicenna's participation in investor conferences indicates potential growth and transparency. One-on-one meetings could signal strategic partnerships or funding opportunities, impacting stock performance.
MDNA11 outperformed a combination of immune checkpoint inhibitors in preventing metastasis and improving long-term survival in a mouse model of triple-negative breast cancer.
MDNA11's superior efficacy over existing treatments in TNBC suggests potential for significant market advantage and future revenue growth, impacting biotech investment strategies.
A 70-year-old patient with advanced chemo-refractory anal cancer achieved complete response in 8 weeks using MDNA11 combined with Merck's KEYTRUDAยฎ (pembrolizumab).
Successful treatment outcomes with MDNA11 and KEYTRUDA may boost investor confidence in the companies involved, potentially leading to increased stock prices and market interest in oncology therapies.
MDNA11 demonstrates significant survival benefits in preclinical glioblastoma models by enhancing CD8+ T and NK cell responses.
MDNA11's success in preclinical glioblastoma models could lead to breakthrough cancer therapies, potentially increasing the value of the company and attracting investment in biotech advancements.
Medicenna Therapeutics will present updated clinical data from its Phase 1/2 ABILITY-1 study at the Immunotherapy Bridge Conference on December 4-5, 2024, in Naples, Italy.
Updated clinical data from Medicenna's Phase 1/2 study could influence investor sentiment and stock performance, reflecting the company's progress in immunotherapy development.
MDNA11 demonstrates strong potential in the ABILITY-1 study, achieving a 30% objective response rate in cancer patients with prior immune checkpoint inhibitor treatment.
MDNA11's strong ORR in a challenging patient group indicates significant clinical efficacy, potentially positioning the drug favorably in the competitive cancer treatment market.
Frequently Asked Questions About MDNAF Stock
What is Medicenna Therapeutics Corp.'s (MDNAF) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Medicenna Therapeutics Corp. (MDNAF) has a median price target of $4.25. The highest price target is $6.00 and the lowest is $2.50.
Is MDNAF stock a good investment in 2025?
According to current analyst ratings, MDNAF has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MDNAF stock?
Wall Street analysts predict MDNAF stock could reach $4.25 in the next 12 months. This represents a 382.4% increase from the current price of $0.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Medicenna Therapeutics Corp.'s business model?
Medicenna Therapeutics Corp. focuses on developing and commercializing advanced immunotherapy treatments, specifically Superkines and empowered Superkines. The company generates revenue through the development of its proprietary therapies, which are designed to enhance the immune response against cancer and other diseases, and by offering its BiSKITs platform for the creation of customized Superkines.
What is the highest forecasted price for MDNAF Medicenna Therapeutics Corp.?
The highest price target for MDNAF is $6.00 from at , which represents a 581.0% increase from the current price of $0.88.
What is the lowest forecasted price for MDNAF Medicenna Therapeutics Corp.?
The lowest price target for MDNAF is $2.50 from at , which represents a 183.8% increase from the current price of $0.88.
What is the overall MDNAF consensus from analysts for Medicenna Therapeutics Corp.?
The overall analyst consensus for MDNAF is bullish. Out of 1 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.25.
How accurate are MDNAF stock price projections?
Stock price projections, including those for Medicenna Therapeutics Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.